Tirzepatide (15 mg Vial) Dosage Protocol

Quickstart Highlights

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite^[1]^[2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing^[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists^[3]^[4].

Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.

Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).

Easy measuring: At 7.5 mg/mL, 1 unit = 0.01 mL = 75 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

Dosing & Reconstitution Guide

Subcutaneous, once weekly

Standard / Gradual Approach (2 mL = 7.5 mg/mL)

Phase	Weekly Dose (mg)	Units (per injection) (mL)
Weeks 1–4	2.5 mg	33 units (0.33 mL) × 1 injection
Weeks 5–8	5 mg	67 units (0.67 mL) × 1 injection
Weeks 9–12	7.5 mg	100 units (1.0 mL) × 1 injection
Weeks 13–16	10 mg	67 units (0.67 mL) × 2 injections

Frequency: Inject once weekly subcutaneously on the same day each week^[1]^[5]. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects^[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Use within 28 days of reconstitution^[6].

Important: This guide is for educational purposes only and is not medical advice.

Supplies Needed

Plan based on an 8–16 week protocol with gradual titration (once‑weekly dosing).

Peptide Vials (Tirzepatide, 15 mg each):

8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 2 vials
12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 4 vials
16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 7 vials

Insulin Syringes (U‑100, 1 mL):

8 weeks: 8 syringes (1/week)
12 weeks: 12 syringes (1/week)
16 weeks: 20 syringes (1/week wks 1–12, 2/week wks 13–16)

Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.

8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
16 weeks (7 vials): 14 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.

Per week: 2 swabs (1 injection day)
8 weeks: 16 swabs → recommend 1 × 100‑count box
12 weeks: 24 swabs → recommend 1 × 100‑count box
16 weeks: 32 swabs → recommend 1 × 100‑count box

View Supplier

Protocol Overview

Concise summary of the once‑weekly regimen.

Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation^[2].

Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.

Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.

Reconstitution: 2.0 mL per 15 mg vial (7.5 mg/mL) for manageable injection volumes.

Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.

Research Disclaimer